Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Wave Life Sciences Ltd. entered into Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) ("GSK") valued at $170 million (effective 2022-12-13).
- Action
- entry
- Agreement
- collaboration
- Counterparty
- GlaxoSmithKline Intellectual Property (No. 3) ("GSK")
- Value
- $170 million
- Effective
- 2022-12-13
Exact text from the filing
On December 13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited (collectively, “ Wave ”), each direct, wholly-owned subsidiaries of Wave Life Sciences Ltd. (the “ Company ”) entered into a Collaboration and License Agreement (the “ Collaboration Agreement ”) with GlaxoSmithKline Intellectual Property (No. 3) (“ GSK ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Wave Life Sciences Ltd. entered into Share Purchase Agreement with Glaxo Group Limited ("GGL") valued at approximately $50 million (effective 2022-12-13).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Glaxo Group Limited ("GGL")
- Value
- approximately $50 million
- Effective
- 2022-12-13
Exact text from the filing
In connection with the parties’ entry into the Collaboration Agreement, the Company has agreed to sell to Glaxo Group Limited (“ GGL ”), an affiliate of GSK, 10,683,761 ordinary shares, no par value (the “ Ordinary Shares ”), for aggregate cash consideration of approximately $50 million, or $4.68 per Ordinary Share (the “ Equity Investment ”), pursuant to the terms of a Share Purchase Agreement, dated December 13, 2022, by and between GGL and the Company (the “ Share Purchase Agreement ”).
View on SEC.gov